arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

enGene Therapeutics Inc.

ENGN

$1.70 ▼ -0.03 (-2.02%) at close

5 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

enGene Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $86.9M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -73.4% ↘

FCF / Share $-1.97 ↘

Trailing P/E 0.7x

Price / Book 0.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

5-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-117.30M

↓ -112.7% —

FCF / Share Free cash flow per share

$-1.97

↓ -51.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health ↓

Cash Quality ↑

Dividend History

Dividend / share · sourced from SEC filings

$0.00 Latest / share

FY 2021

FY 2022

$0.00

FY 2023

$0.00

FY 2024

$0.00

FY 2025

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Oct 31, 2025 10-K ↗	FY 2024 Oct 31, 2024 10-K ↗	FY 2023 Oct 31, 2023 10-K ↗	FY 2022 Oct 31, 2022 10-K ↗	FY 2021 Oct 31, 2021 10-K ↗
EPS Growth YoY (%)	56.8% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	-99.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	241.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-112.7% Weak ↑ Weak Improving Year-over-year change in net income	44.8% Excellent Excellent Year-over-year change in net income	-308.5% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-51.3% Weak ↓ Weak Declining Year-over-year change in free cash flow	96.4% Excellent Excellent Year-over-year change in free cash flow	-33.6% Weak Weak Year-over-year change in free cash flow	—	—
EPS CAGR 3Y (%)	-62.7% Weak Weak Compound annual EPS growth over 3 years	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Oct 31, 2025 10-K ↗	FY 2024 Oct 31, 2024 10-K ↗	FY 2023 Oct 31, 2023 10-K ↗	FY 2022 Oct 31, 2022 10-K ↗	FY 2021 Oct 31, 2021 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	0.86x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.25x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Oct 31, 2025 10-K ↗	FY 2024 Oct 31, 2024 10-K ↗	FY 2023 Oct 31, 2023 10-K ↗	FY 2022 Oct 31, 2022 10-K ↗	FY 2021 Oct 31, 2021 10-K ↗
Return on Invested Capital (%)	-73.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-22.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-36.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	25.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-55.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-20.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-30.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-81.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-69.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-566%)	-20.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-235%)	-137.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1019%)	31.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+113%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Oct 31, 2025 10-K ↗	FY 2024 Oct 31, 2024 10-K ↗	FY 2023 Oct 31, 2023 10-K ↗	FY 2022 Oct 31, 2022 10-K ↗	FY 2021 Oct 31, 2021 10-K ↗
Interest Coverage (x)	-53.81x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-32.36x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-5.26x Weak Weak Operating income divided by interest expense Optimal: > 5x	-13.65x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-50.15M	$-173.00M	$-81.52M	$-20.43M	—

📊 What does each share earn? 7 metrics

Metric	FY 2025 Oct 31, 2025 10-K ↗	FY 2024 Oct 31, 2024 10-K ↗	FY 2023 Oct 31, 2023 10-K ↗	FY 2022 Oct 31, 2022 10-K ↗	FY 2021 Oct 31, 2021 10-K ↗
Basic EPS, GAAP (USD)	$2.29	$1.46	$151.22	$44.30	—
Free Cash Flow per Share (USD)	$-1.97	$-1.30	$-36.18	$-27.09	—
Dividend per Share (USD)	$0.00	$0.00	$0.00	—	—
Book Value per Share (USD)	$3.22	$5.35	$3.12	$-115.08	—
Tangible Book Value per Share (USD)	$3.22	$5.35	$3.12	$-115.08	—
Basic Weighted Avg Shares (shares)	51.12M	37.78M	692,609	655,153	—
Dividend Payout Ratio (%)	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Oct 31, 2025 10-K ↗	FY 2024 Oct 31, 2024 10-K ↗	FY 2023 Oct 31, 2023 10-K ↗	FY 2022 Oct 31, 2022 10-K ↗	FY 2021 Oct 31, 2021 10-K ↗
Working Capital (USD)	$169.41M	$232.70M	$80.18M	$17.48M	—
Total Equity (USD)	$167.71M	$272.61M	$72.49M	$-76.61M	$-53.44M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Oct 31, 2025 10-K ↗	FY 2024 Oct 31, 2024 10-K ↗	FY 2023 Oct 31, 2023 10-K ↗	FY 2022 Oct 31, 2022 10-K ↗	FY 2021 Oct 31, 2021 10-K ↗
Depreciation Expense (USD)	$500.00K	$300.00K	$200.00K	$200.00K	—
Net Income, GAAP (USD)	$-117.30M	$-55.14M	$-99.92M	$-24.46M	—
Operating Cash Flow (USD)	$-99.24M	$-48.28M	$-24.74M	$-17.59M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 5 years · 17 quarters

enGene Therapeutics Inc.

Analytical Summary

5-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Dividend History

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ENGN with peers